Today, shares of Ariad Pharmaceuticals (NASDAQ:ARIA) have crossed bullishly above their 10-day moving average of $19.88 on a volume of 480K shares. Swing traders may find an opportunity for a long position, as such a crossover often suggests higher prices in the near term.
ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.
In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $13.92 and a high of $25.40 and are now at $20.19, 45% above that low price. The 200-day and 50-day moving averages have moved 0.39% higher and 0.35% lower over the past week, respectively.
Ariad Pharmaceuticals has overhead space with shares priced $20.19, or 28.4% below the average consensus analyst price target of $28.20. The stock should hit resistance at its 50-day moving average (MA) of $20.68, as well as support at its 200-day MA of $19.77.